



Form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/077,154
		Filing Date	February 15, 2002
		First Named Inventor	Timothy J. Martins
		Group Art Unit	1626
		Examiner Name	Unassigned E
Sheet	1	of	2
		Attorney Docket Number	27866/38184

RECEIVED
 JUN 11 2002
 TECH CENTER 1000 2900


Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code (if known)		
B		3,935,217	01/27/76	Nakanishi et al.
B		5,685,754	09/09/97	Feldman et al.
B		5,998,428	12/07/99	Barnette et al.

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY
B		0 671 389 (EPO)	09/13/95
B		WO 92/19594 (PCT)	11/12/92
B		WO 95/08534 (PCT)	03/30/95
B		WO 97/25312 (PCT)	07/17/97

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
B		J.E. Schultz et al., <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , 333, pp. 23-30 (1986).
		Z. Ma et al., <i>Tetrahedron: Asymmetry</i> , Vol. 8, No. 6, pp. 883-887 (1997).
		A. Roblchaud et al., <i>Neuropharmacology</i> , 38, pp. 289-297 (1999).
		R.A. Allen et al., <i>Biochemical Pharmacology</i> , Vol. 57, pp. 1375-1382 (1999).
		J. Beavo et al., "Cyclic nucleotide phosphodiesterases: Structure, regulation and drug action," Wiley and Sons, Chichester, pp. 3-14 (1990).
		T.J. Torphy et al., <i>Drug News and Perspectives</i> , 6, pp. 203-214 (1993).
		M.A. Glembycz et al., <i>Clin. Exp. Allergy</i> , 22, pp. 337-344 (1992).
		J. Semmler et al., <i>Int. J. Immunopharmacol.</i> , 15, pp. 409-413 (1993).
		K.L. Molnar-Kimber et al., <i>Mediators of Inflammation</i> , 1, pp. 411-417 (1992).
		M.W. Verghese et al., <i>J. Mol. Cell Cardiol.</i> , 21 (Suppl. 2), S61 (1989).
		C.P. Nielson et al., <i>J. Allergy Immunol.</i> , 86, pp. 801-808 (1990).
		P.T. Peachell et al., <i>J. Immunol.</i> , 148, pp. 2503-2510 (1992).
		G. Dent et al., <i>J. Pharmacol.</i> , 103, pp. 1339-1346 (1991).
		S.A. Robicsek et al., <i>Biochem. Pharmacol.</i> , 42, pp. 869-877 (1991).
		H.S. Dhillon et al., <i>J. Neurotrauma</i> , 12, pp. 1035-1043 (1995).
		N. Suttrop et al., <i>J. Clin. Invest.</i> , 91, pp. 1421-1426 (1993).
		M.R. Bristow et al., <i>Circulation</i> , 97, pp. 1340-1341 (1998).
B		G. Poli et al., <i>Proc. Natl. Acad. Sci. USA</i> , 87, pp. 782-785 (1990).

Examiner Signature	<i>Thomas Backy</i>	Date Considered	1/8/03
-----------------------	---------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449B/P TO				Complete If Known Application Number 10/077,154 Filing Date February 15, 2002 First Named Inventor Timothy J. Martins Group Art Unit 1626 Examiner Name Unassigned E. S. [unclear] Attorney Docket Number 27866/38184	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				JUN 13 2002 TECH CENTER 1500/2800 RECEIVED	
Sheet	2	of	2		

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume- issue number(s), publisher, city and/or country where published.
ES		P. Orosz et al., <i>J. Exp. Med.</i> , 177, pp. 1391-1398 (1993).
		M. Mentz et al., <i>Blood</i> , 88, pp. 2172-2182 (1996).
		S. Takeda et al., <i>Kidney Int.</i> , 37, p. 362 (1990).
		D. Chabardea et al., <i>Kidney Int.</i> , 35, p. 494 (1989).
		C.D. Nicholson, <i>Psychopharmacology</i> , 101, p. 147 (1990).
		F. Eckmann et al., <i>Curr. Ther. Res.</i> , 43, p. 291 (1988).
		A. Kłodzinska et al., <i>Neuropharmacology</i> , 38, p. 1831 (1991).
		H. Kato et al., <i>Eur. J. Pharmacol.</i> , 272, p. 107 (1995).
		G. Gardos et al., <i>J. Clin. Pharmacol.</i> , 16, p. 304 (1976).
		I. Shoulson et al., <i>Neurology</i> , 25, p. 722 (1975).
		T. Hayakawa et al., <i>Clin. Exp. Pharmacol. Physiol.</i> , 26, p. 421 (1999).
		R.D. Porsolt et al., <i>Eur. J. Pharmacol.</i> , 47, p. 379 (1978).
		R.D. Porsolt et al., <i>Eur. J. Pharmacol.</i> , 57, p. 431 (1979).
		L. Steru, <i>Psychopharmacology</i> , 85, p. 376 (1985).
		M. Takahashi, <i>J. Neuroscience</i> , 19, p. 610 (1999).
		D. Pinsky et al., <i>J. Clin. Invest.</i> , 92, pp. 2994-3002 (1993).
ES		<i>Antidepressants: neurochemical, behavioral and clinical perspectives</i> , Enna, Malick, and Richelson, eds., Raven Press, pp. 121-139 (1981).

Examiner Signature	<i>Joseph J. [unclear]</i>	Date Considered	1/8/03
--------------------	----------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.